atai Life Sciences Announces Initiation of Phase 1 Trial for its MDMA Derivative, EMP-01 Post published:September 27, 2022 Post category:Press Release
Clearmind Announces Notice of Proposed Stock Consolidation Post published:September 26, 2022 Post category:Press Release
MYDECINE INNOVATIONS GROUP ANNOUNCES CLOSING UNDER SHARE SUBSCRIPTION AGREEMENT AND WELCOMES NEW CFO Post published:September 24, 2022 Post category:Press Release
Clearmind Applies for Patent to Treat Obesity and Metabolic Syndrome Post published:September 23, 2022 Post category:Press Release
Delix Therapeutics Expands World-Class Team with First Head of R&D Post published:September 23, 2022 Post category:Press Release
Numinus Expands Ketamine Therapy for Mental Health in Montreal and announces new brand awareness initiatives USA – English USA – English USA – English España – español Latin America – español Post published:September 23, 2022 Post category:Press Release
Psyence Group Completes Export of Psilocybin Mushrooms to Canada Post published:September 22, 2022 Post category:Press Release
Optimi Health, ATMA Journey Centers To Proceed With Phase I Natural Psilocybin and MDMA Clinical Trial Application to Health Canada Post published:September 22, 2022 Post category:Press Release
Braxia Scientific Announces Board Appointment Post published:September 22, 2022 Post category:Press Release
Algernon Pharmaceuticals Announces Receipt of CDN $450K Cash Refund from Australian Research Program Post published:September 21, 2022 Post category:Press Release